Chordoma Disease Therapeutics Market, by Drug Class (Antimetabolites, Anthracycline, VEGFR Inhibitors, EGFR Inhibitor, and Others), by Treatment Type (Chemotherapy, Targeted Therapy, Radiation Therapy, and Others), by End User (Hospitals, Clinics, Oncology Centers, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : Jul 2023

Code : CMI3979

Pages :180

Formats :

Excel and PDF

Industry : Pharmaceutical

Market News

Global Chordoma Disease Therapeutics Market: Key Developments

On May 31, 2023, Boehringer Ingelheim International, a pharmaceutical company, developed Afatinib dimaleate, a 4-anilinoquinazoline, antineoplastic agent. It is formulated as film coated tablets for oral route of administration. It is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) tumors have epidermal growth factor receptor (EGFR) exon-19 deletions or exon-21 (L858R) substitution mutations as detected by an US FDA-approved test, indicated as monotherapy for the treatment of Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor naïve patients with metastatic (including cytologically proven pleural effusion) adenocarcinoma of the lung with activating EGFR mutation(s).

In December 2020, Bavarian Nordic A/S, a integrated vaccine company focused on the development, manufacturing and commercialization of life-saving vaccines in Denmark, announced top-line results from a Phase 2 clinical study evaluating the targeted immunotherapy candidate, BN-Brachyury in the treatment of advanced chordoma, a rare cancer occurring in the base of the skull and spine. While the study failed to meet its primary endpoint, it provided evidence of clinical activity.

On June 1, 2023, Myriad Genetics, Inc., is a company of genetic testing and precision medicine, launched new studies and expansion of its Precise Oncology Solutions portfolio at the 2023 American Society of Clinical Oncology (ASCO).

On March 22, 2023, F. Hoffmann-La Roche Ltd (Roche), a biotechnology company that develops drugs and diagnostics to treat major diseases, announced that it has entered into a collaboration with Eli Lilly and Company is pharmaceutical company headquartered in U.S. to support the development of Roche’s Elecsys chordoma disease therapeutics.

In March 2022, Invitae, a medical genetics company, announced full access to its Personalized Cancer Monitoring (PCMTM) platform to help detect minimal or molecular residual disease (MRD) in patients with solid tumors. Invitae PCM uses a novel set of personalized assays based on a patient's tumor to detect circulating tumor DNA (ctDNA) in blood, offering the ability to perform risk stratification, response assessment to treatment and detection of cancer recurrence, based on recent studies.

Global Chordoma Disease Therapeutics Market: Key Trends

Application of biomarker test for diagnosing chordoma disease

Application of biomarker test for diagnosing chordoma disease is expected to propel growth of the global chordoma disease therapeutics market over the forecast period. Major players in the market are focused on adopting partnership strategies to expand its product portfolio. Presently, there is no drugs available for the diagnosis of chordoma disease. However, anti–cyclic citrullinated peptide (anti–CCP) antibodies test require more refinement to improve its clinical utility. For instance, in March 2020, WorldCare Clinical, LLC, an independent contract research organization offering imaging in clinical trials, partnered with Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immuno-therapeutics, to offer imaging service following U.S. FDA approval of Navidea’s cancer diagnostic. Navidea’s strategy is to deliver novel products and advancing the company’s pipeline through global partnering with WorldCare Clinical, LLC.